Synthetic Biologics, Inc. (SYN): Price and Financial Metrics


Synthetic Biologics, Inc. (SYN): $0.22

0.01 (+2.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SYN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SYN Stock Price Chart Interactive Chart >

Price chart for SYN

SYN Price/Volume Stats

Current price $0.22 52-week high $0.72
Prev. close $0.21 52-week low $0.20
Day low $0.21 Volume 238,300
Day high $0.22 Avg. volume 2,369,675
50-day MA $0.26 Dividend yield N/A
200-day MA $0.33 Market Cap 34.56M

Synthetic Biologics, Inc. (SYN) Company Bio


Synthetic Biologics, Inc. is a clinical stage company developing therapeutics which protect microbiomes and target pathogen-specific diseases. The Company develops drugs that are designed to reduce the impact of methane-producing organisms to help treat the cause of IBS-C and designed to protect microbiomes and prevent CDI during IV antibiotic use.


SYN Latest News Stream


Event/Time News Detail
Loading, please wait...

SYN Latest Social Stream


Loading social stream, please wait...

View Full SYN Social Stream

Latest SYN News From Around the Web

Below are the latest news stories about Synthetic Biologics Inc that investors may wish to consider to help them evaluate SYN as an investment opportunity.

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that the Company will be presenting at the 2022 BIO CEO & Investor Conference being held February 14-17, 2022. The conference will be conducted as a hybrid event at the New York Marriott Marquis and virtually.

Yahoo | February 9, 2022

Synthetic Biologics says VCN's therapy for retinoblastoma gets FDA's orphan drug status

Synthetic Biologics (NYSE:SYN) said VCN Biosciences' VCN-01 received the U.S. Food & Drug Administration's (FDA) orphan drug designation for retinoblastoma, a type of eye cancer. Synthetic Biologics is in the process of acquiring VCN. "We are highly encouraged by the preliminary clinical data thus far and look forward to conducting a pivotal Phase 2/3 trial...

Seeking Alpha | February 8, 2022

Synthetic Biologics Announces VCN Biosciences'' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA

ROCKVILLE, Md., Feb. 8, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that VCN Biosciences, S.L.''s (VCN) VCN-01 received Orphan Drug…

PR Newswire | February 8, 2022

Synthetic Biologics says VCN''s therapy for retinoblastoma gets FDA''s orphan drug status

Synthetic Biologics (SYN) said VCN Biosciences'' VCN-01 received the U.S

Seeking Alpha | February 8, 2022

Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that VCN Biosciences, S.L.'s (VCN) VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. Food & Drug Administration (FDA). This announcement follows Synthetic Biologics' recent announcement that it had entered a definitive agreement to acquire VCN, which is subject to conditions that must be met pri

Yahoo | February 8, 2022

Read More 'SYN' Stories Here

SYN Price Returns

1-mo -10.75%
3-mo -7.56%
6-mo -36.23%
1-year -58.10%
3-year -59.75%
5-year -98.97%
YTD -19.18%
2021 -28.93%
2020 -24.44%
2019 -9.48%
2018 -96.86%
2017 -32.89%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5784 seconds.